Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06643208 | D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC | recruiting | — | 37 | Fujian Provincial HospitalOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07018518 | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06168292 | Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma | recruiting | N/A | 53 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07025174 | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer(SAIB) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07007832 | Bile Omics for Diagnosing Indeterminate Biliary Strictures | recruiting | — | 260 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04348838 | Prospective Cohort of Patients With Hepatocellular Carcinoma in France(CHIEF) | recruiting | — | 5,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010198 | Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City | recruiting | — | 4,500 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06999707 | Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC(Photon-STRIDE) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06988592 | GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）(BTC-IM-1) | recruiting | — | 100 | Fudan UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06995105 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06277531 | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)(ECCBILE) | recruiting | — | 99 | Peking University Third HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma(HAICI) | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06986486 | Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma(pCOLA) | recruiting | — | 8 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06978933 | FGF19 Overexpression Combination Unified Study in HCC-19(FOCUS-19) | recruiting | Phase 2 | 42 | RenJi HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06251115 | Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC | recruiting | N/A | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05763277 | Ate-Bev Early Response Prediction Model in Advanced HCC | recruiting | — | 170 | Seoul National University HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06280105 | A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib | recruiting | Phase 2 | 40 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06406816 | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection | recruiting | Early Phase 1 | 10 | Yongyi ZengOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06339424 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma(PhotonAB) | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06379256 | Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy | recruiting | — | 300 | Chang Gung Memorial HospitalOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06383520 | Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma | recruiting | Early Phase 1 | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 24 | Yoon Jun KimOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05409482 | A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma | recruiting | — | 300 | Meng Chao Hepatobiliary Hospital of Fujian Medical UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06961526 | Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab | recruiting | N/A | 110 | Tanta UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06961617 | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | recruiting | Phase 2 | 51 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06960863 | Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma | recruiting | — | 80 | Tanta UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04037007 | Efficacy of Fistulotomy for Biliary Cannulation | recruiting | N/A | 320 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | May 1, 2025 | clinicaltrials |
| NCT06420440 | Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model | recruiting | Phase 2 | 160 | Chen XiaopingOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | recruiting | Phase 2 / Phase 3 | 180 | InnoPharmax Inc.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06950814 | Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma | recruiting | — | 50 | West China HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06950827 | Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma | recruiting | — | 400 | West China HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06904196 | Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC | recruiting | Phase 2 | 78 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06418659 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients | recruiting | Early Phase 1 | 37 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06583993 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients | recruiting | Early Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06822413 | Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis | recruiting | — | 600 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06940102 | Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors | recruiting | — | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06909708 | SIRT Versus cTACE for Unresectable HCC (CHANCE2506) | recruiting | N/A | 108 | Zhongda HospitalOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05687747 | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | recruiting | Phase 1 | 100 | National University Hospital, SingaporeOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05828446 | Improving Hepatocellular Carcinoma Screening(AMRIK) | recruiting | N/A | 330 | Naik Vietti VioliOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06898398 | TACE Combined Surgery for the Resectable Huge HCC | recruiting | — | 326 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2025source: clinicaltrials